The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Study efficacy measures will include the expression of dystrophin protein and motor function.
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
Subscribe To Our Newsletter & Stay Updated
